Manufacturer of Controlled Substances; Notice of Application, 43814 [E6-12459]

Download as PDF 43814 Federal Register / Vol. 71, No. 148 / Wednesday, August 2, 2006 / Notices controlled substances listed in Schedules II: Drug Schedule Methylphenidate (1724) ................ Phenylacetone (8501) .................. Methadone intermediate (9254) ... II II II The company plans to manufacture the listed controlled substance in bulk for sale to its customer. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC. 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 2, 2006. Dated: July 26, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–12455 Filed 8–1–06; 8:45 am] BILLING CODE 4410–09–P should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC. 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 2, 2006. Dated: July 26, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–12457 Filed 8–1–06; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration BILLING CODE 4410–09–P Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 19, 2006, Orasure Technologies, Inc., Lehigh University, Seeley G. MuddBuilding 6, Bethlehem, Pennsylvania 18015, made application by renewal, and by letter, to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedule I and II: DEPARTMENT OF JUSTICE Drug wwhite on PROD1PC61 with NOTICES Manufacturer of Controlled Substances; Notice of Application Pursuant to Section 1301.33(a) Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 27, 2006, Noramco Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of basic drug code (1724) methylphenidate. The company plans to bulk manufacture methylphenidate for a customer to use in the production of a controlled substance product. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail VerDate Aug<31>2005 16:40 Aug 01, 2006 Jkt 208001 Dated: July 26, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–12459 Filed 8–1–06; 8:45 am] Manufacturer of Controlled Substances; Notice of Application DEPARTMENT OF JUSTICE Drug Enforcement Administration may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC. 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 2, 2006. Schedule Lysergic acid diethylamide (LSD) (7315). 4–Methoxyamphetamine (7411) ... Normorphine (9313) ..................... Tetrahydrocannabinols (THC) (7370). Alphamethadol (9605) .................. Amphetamine (1100) .................... Methamphetamine (1105) ............ Cocaine (9041) ............................. Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... Hydrocodone (9193) ..................... Morphine (9300) ........................... Oxycodone (9143) ........................ Meperidine (9230) ........................ Methadone (9250) ........................ Oxymorphone (9652) ................... I I I I I II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk to manufacture controlled substance derivatives. These derivatives will be used in diagnostic products created specifically for internal use only. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance PO 00000 Frm 00105 Fmt 4703 Sfmt 4703 Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 10, 2006, Siegfried (USA), Inc., Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedule II: Drug Amphetamine (1100) .................... Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Glutethimide (2550) ...................... Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Methadone intermediate (9254) ... Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Schedule II II II II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the E:\FR\FM\02AUN1.SGM 02AUN1

Agencies

[Federal Register Volume 71, Number 148 (Wednesday, August 2, 2006)]
[Notices]
[Page 43814]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-12459]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on February 19, 2006, Orasure 
Technologies, Inc., Lehigh University, Seeley G. Mudd-Building 6, 
Bethlehem, Pennsylvania 18015, made application by renewal, and by 
letter, to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of the basic classes of controlled substances 
listed in Schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide (LSD) (7315)....  I
4-Methoxyamphetamine (7411)................  I
Normorphine (9313).........................  I
Tetrahydrocannabinols (THC) (7370).........  I
Alphamethadol (9605).......................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Cocaine (9041).............................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Oxycodone (9143)...........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Oxymorphone (9652).........................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk to manufacture controlled substance derivatives. These 
derivatives will be used in diagnostic products created specifically 
for internal use only.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR Sec.  1301.33(a).
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC. 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
Virginia 22301; and must be filed no later than October 2, 2006.

    Dated: July 26, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E6-12459 Filed 8-1-06; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.